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The concept of altered immune function of the intestine during the administration of parenteral nutrition (PN) has been demonstrated by a number 
of researchers over the past 2 decades.1,2 Deterioration of 
the gut-associated lymphoid tissue (GALT) can have pro-
found consequences on local (gastrointestinal [GI]) and 
system (pulmonary) immune functions and the organ-
ism’s ability to protect the host due to a breakdown in the 
GI tract’s barrier function.3,4 Such a breakdown in this 
barrier function and decline of intestinal and pulmonary 
immunoglobulin A (IgA) production can lead to the host’s 
susceptibility to a number of bacterial and viral infec-
tions.5,6 Mechanisms that mediate this PN-associated loss 
in immune functionality within the GI tract can result 
because of a shift in cytokine production with a loss of 
interleukin-7 (IL-7),7,8 IL-4, and IL-101,3 and an increase 
in proinflammatory cytokines, including interferon-γ 
(IFN-γ)9 and tumor necrosis factor-α (TNF-α).10,11 Such a 
shift in cytokines may well mediate many of these adverse 
PN effects, and strategies to prevent these changes have 
been approached in a variety of ways.
Although small amounts of a complex diet can prevent 
PN-associated changes to GALT,11,13 this strategy may not 
always be clinically possible. Thus, strategies to modify 
current PN solutions with additional factors have been a 
focus of the Fukatsu laboratory and others. Other strate-
gies that can prevent the GALT from changing with PN 
administration include use of arginine-supplemented PN,14 
glutamine-supplemented PN,15,16 exogenous administra-
tion of GI hormones including bombesin17 or glucagon-like 
peptide-2,18-20 or exogenous IL-7.21 Such approaches have 
benefits but also several obstacles, including cost, lack of 
approval from the U.S. Food and Drug Administration, and 
safety concerns.
In this issue of the Journal and Parenteral and Enteral 
Nutrition (JPEN), Murakoshi et al22 studied the ability to 
alter the composition of the PN solution with the addition 
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of butyric acid and the subsequent alteration of the 
GALT, pulmonary production of IgA, and intestinal crypt/
villus architecture. For more than a decade, the strategy 
of using short-chain fatty acids (SCFAs) with PN has 
been shown to have the potential to prevent several 
PN-associated adverse changes.23,24 SCFAs can increase 
epithelial cell transporter activity, including the glucose 
transporter 2, and elevate the production of progluca-
gon.23 Further work in this area has shown that butyrate 
is the key SCFA that can mediate many of these changes, 
including the ability to augment intestinal adaptation 
after a major intestinal resection.25 The mechanisms by 
which butyrate works have not been fully elucidated; 
however, a number of experiments have shown that the 
actions of butyrate are complex and multifactorial.26 In 
fact, butyrate can augment epithelial cell proliferation, a 
point that is also suggested by the preservation of intesti-
nal architecture by Murakoshi et al22 in this issue of 
JPEN. Butyrate has other potentially beneficial actions 
that can improve the overall composition of the luminal 
microbiota, sustain epithelial integrity, improve defense 
mechanisms, and even downregulate bacterial virulence.26 
As we now see in this publication, administration of 
butyrate with the PN solution can partially prevent the 
loss the local GALT system.
The Fukatsu et al study helps to pave a potential 
pathway for the development of future PN formulations 
supplemented with butyrate. Clearly, the challenges will 
be to better understand the mechanisms by which butyrate 
mediates its intestinal action and to ensure a high level of 
safety with its administration.
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